RA Capital Nexus Fund II, L.P. Insider Trading -- Recent SEC Form 4 Transactions
RA Capital Nexus Fund II, L.P. (CIK 1825376) reported 35 SEC Form 4 insider transactions across 8 companies over the past 18 months (most recent 2026-09-30). Recent activity: Buy CLYM (10,000 shares), Buy CLYM (10,000 shares), Buy CLYM (10,000 shares), Buy CLYM (40,000 shares), Buy FRNM (6.6M shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-30 | Climb Bio, Inc. (CLYM) | Director | Buy | 10,000 | $34,600 |
| 2026-09-30 | Climb Bio, Inc. (CLYM) | Director | Buy | 10,000 | $30,000 |
| 2026-09-30 | Climb Bio, Inc. (CLYM) | Director | Buy | 10,000 | $78,900 |
| 2026-09-30 | Climb Bio, Inc. (CLYM) | Director | Buy | 40,000 | $51,600 |
| 2026-07-22 | Freenome, Inc. (FRNM) | Director | Buy | 6.6M | $0 |
| 2026-07-22 | Freenome, Inc. (FRNM) | Director | Buy | 970,950 | $0 |
| 2026-07-22 | Freenome, Inc. (FRNM) | Director | Buy | 553,703 | $0 |
| 2026-07-22 | Freenome, Inc. (FRNM) | Director | Buy | 908,103 | $0 |
| 2026-07-22 | Freenome, Inc. (FRNM) | Director | Buy | 367,427 | $0 |
| 2026-07-22 | Freenome, Inc. (FRNM) | Director | Buy | 4.9M | $49.2M |
| 2026-07-22 | Freenome, Inc. (FRNM) | Director | Buy | 336,965 | $3.4M |
| 2026-06-12 | Janux Therapeutics, Inc. (JANX) | Director | Buy | 5,500 | $0 |
| 2026-06-05 | Acumen Pharmaceuticals, Inc. (ABOS) | Director | Buy | 35,500 | $0 |
| 2026-05-20 | Acrivon Therapeutics, Inc. (ACRV) | Director | Buy | 9,366 | $0 |
| 2026-05-06 | Hemab Therapeutics Holdings, Inc. (COAG) | Director | Buy | 3.6M | $0 |
| 2026-05-06 | Hemab Therapeutics Holdings, Inc. (COAG) | Director | Buy | 1.0M | $0 |
| 2026-05-06 | Hemab Therapeutics Holdings, Inc. (COAG) | Director | Buy | 221,188 | $0 |
| 2026-05-06 | Hemab Therapeutics Holdings, Inc. (COAG) | Director | Buy | 2.5M | $45.7M |
| 2026-05-06 | Hemab Therapeutics Holdings, Inc. (COAG) | Director | Buy | 133,750 | $2.4M |
| 2026-05-06 | Hemab Therapeutics Holdings, Inc. (COAG) | Director | Buy | 87,143 | $2.1M |
| 2026-05-06 | Hemab Therapeutics Holdings, Inc. (COAG) | Director | Buy | 10,268 | $256,700 |
| 2026-05-06 | Hemab Therapeutics Holdings, Inc. (COAG) | Director | Buy | 14,611 | $347,303 |
| 2026-05-06 | Hemab Therapeutics Holdings, Inc. (COAG) | Director | Buy | 53,407 | $1.3M |
| 2026-04-23 | Acrivon Therapeutics, Inc. (ACRV) | Director | Buy | 3.9M | $7.0M |
| 2026-03-18 | Acumen Pharmaceuticals, Inc. (ABOS) | Director | Buy | 6.1M | $20.0M |
Source: SEC Form 4 filings · as of 2026-09-30